Adipotide

Adipotide, also known as FTPP (fat-targeted proapoptotic peptide), is a research peptide designed to selectively destroy the blood vessels that supply white adipose tissue. It was developed at MD Anderson Cancer Center by Wadih Arap and Renata Pasqualini's lab as a proof-of-concept for targeted vascular ablation. The molecule consists of a homing sequence that recognizes a receptor expressed on fat-tissue vasculature, fused to a small pro-apoptotic sequence that triggers cell death once delivered. It is sold strictly for laboratory research.

Fat tissue, like every other tissue, needs a blood supply to survive. Adipotide is a research peptide that acts like a guided missile: the targeting end finds the blood vessels feeding white fat, and the warhead end tells those specific vessel cells to self-destruct. Without their blood supply, the fat cells shrink and die. In obese monkey studies, Adipotide produced significant fat loss in about a month. The mechanism is dramatic and very different from how GLP-1 drugs like semaglutide work — those reduce appetite; Adipotide attacks the fat tissue itself.

Adipotide is a chimeric peptide combining a homing motif (CKGGRAKDC) that binds prohibitin on adipose vasculature with a pro-apoptotic sequence (KLAKLAK)2 that disrupts mitochondrial membranes once internalized. The result is selective apoptosis of endothelial cells in fat-tissue blood vessels, leading to involution of the white adipose depot. Rhesus monkey studies showed weight loss of roughly 11% over four weeks. However, the same kidney vasculature expresses prohibitin, which produced concerning renal effects in those studies.

• •Obesity research in non-human primates
• •Vascular-targeted drug delivery
• •Adipose tissue angiogenesis
• •Prohibitin receptor biology
• •Pro-apoptotic peptide design

Adipotide is a recurring 'holy grail' name in fat-loss forum discussions, especially in the wake of the GLP-1 revolution. Threads typically reference the monkey studies, then quickly pivot to the kidney safety concerns that have kept it out of human trials. Compared to semaglutide and tirzepatide, which have years of human data, Adipotide is more of a research curiosity than a viable clinical compound. Some grey-market suppliers list it; the consensus on r/Peptides is to treat it as high-risk and largely theoretical.

“A guided missile that kills fat tissue's blood supply.”

Adipotide is rarely stacked. The mechanism is aggressive enough that pairing it with other compounds is generally avoided in research discussions. Some forum users theorize pairing it with a GLP-1 agonist for appetite control during a treatment window, but no published research supports this.

Adipotide (FTPP) is a research peptide that selectively kills the blood vessels supplying white adipose tissue, producing significant fat loss in animal models. Kidney safety concerns have limited human development, and it is sold strictly for laboratory research.